Efficacy of duloxetine in patients with fibromyalgia: Pooled analysis of 4 placebo-controlled clinical trials

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 11, Issue 5, 2009, Pages 237-243

  Arnold, Lesley M ^a   Clauw, Daniel J ^b   Wohlreich, Madelaine M ^c   Wang, Fujun ^c   Ahl, Jonna ^c   Gaynor, Paula J ^c   Chappell, Amy S ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862908787     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.08m00680     Document Type: Article

References (33)

1. Yunus M, Masi AT, Calabro JJ, et al. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum. 1981;11(1):151-171.
2. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum. 1990;33(2):160-172.
3. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005;75:6-21.
4. Goldenberg DL, Simms RW, Geiger A, et al. High frequency of fibro-myalgia in patients with chronic fatigue seen in primary care practice. Arthritis Rheum. 1990;33(3):381-387.
5. Wolfe F, Ross K, Anderson J. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1): 19-28.
6. Burckhardt CS, Clark SR, Bennett RM. Fibromyalgia and quality of life: a comparative analysis. J Rheumatol. 1993;20(3):475-479.
7. Bennett RM. Fibromyalgia and the disability dilemma: a new era in understanding a complex, multidimensional pain syndrome. Arthritis Rheum. 1996;39(10):1627-1634.
8. Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. 2007;61(9): 1498-1508.
9. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep. 2002;4(4):299-305.
10. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci. 1984;7: 309-338.
11. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66(6): 355-474.
12. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med. 2000;32(5):305-316.
13. Wong DT, Bymaster FP, Mayle DA, et al. LY248686: a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993;8(1):23-33.
14. Iyengar S, Webster AA, Hemrick-Luecke SK, et al. Efficacy of dulox-etine: a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther. 2004;311(2): 576-584.
15. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1-2):109-118.
16. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multi-center trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6(5):346-356.
17. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411-1420.
18. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974-2984.
19. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005; 119(1-3):5-15.
20. Russell IJ, Mease P, Smith T, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432-444.
21. Chappell AS, Bradley LA, Wiltse C, et al. A 27-week, placebo-controlled clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med. 2008;1:91-102
22. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol. 1991;18(5): 728-733.
23. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129-138.
24. Guy W (ed). Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised. Publication Adm 76-338. Washington, DC: US Department of Health, Education, and Welfare; 1976.
25. Beck AT, Steer RA, Ball R, et al. Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients. J Pers Assess. 1996;67(3):588-597.
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
27. Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
28. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(suppl 3):89-95.
29. Wolfe F, Ross K, Anderson J, et al. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol. 1995;22(1):151-156.
30. Yunus MB, Inanici F, Aldag JC, et al. Fibromyalgia in men: comparison of clinical features with women. J Rheumatol. 2000;27(2):485-490.
31. Gansky SA, Plesh O. Widespread pain and fibromyalgia in a biracial cohort of young women. J Rheumatol. 2007;34(4):810-817.
32. Raphael KG, Janal MN, Nayak S, et al. Psychiatric comorbidities in a community sample of women with fibromyalgia. Pain. 2006;124 (1-2):117-125.
33. Arnold LM. Biology and therapy of fibromyalgia: new therapies in fibromyalgia. Arthritis Res Ther. 2006;8(4):212.